Urinary trypsin inhibitor and urokinase activities in renal diseases.
Using an improved method of determination, urinary trypsin inhibitor (UTI) activities were assayed in relation to urokinase (UK) activities in a large group of patients with various renal diseases. In normal subjects (n = 50), the mean 24-hour values of the UTI and UK activities were 4.29 +/- 1.44 U/ml and 9.80 +/- 3.81 IU/ml, respectively. Data for renal diseases such as renal stone, hydronephrosis, renal cancer, and chronic glomerulonephritis (UTI, 5.51 +/- 2.29 U/ml (p less than 0.005) and UK, 6.88 +/- 2.64 IU/ml (p less than 0.001); n = 40), and particularly uremia (UTI, 9.90 +/- 5.68 U/ml (p less than 0.001) and UK, 3.85 +/- 2.36 IU/ml (p less than 0.001); n = 30), showed that the UTI level was increased whereas the UK level was decreased. The UTI/UK ratio more clearly demonstrated the difference between these diseases.
D000906:Antibodies; D000933:Antifibrinolytic Agents / Q000652:urine; D002908:Chronic Disease; D010450:Endopeptidases / Q000378:metabolism*; D005260:Female; D005921:Glomerulonephritis / Q000201:enzymology; D006801:Humans; D006869:Hydronephrosis / Q000201:enzymology; D007669:Kidney Calculi / Q000201:enzymology; D007674:Kidney Diseases / Q000201:enzymology*; D007680:Kidney Neoplasms / Q000201:enzymology; D008297:Male; D014361:Trypsin Inhibitors / Q000276:immunology / Q000378:metabolism / Q000652:urine*; D014511:Uremia / Q000201:enzymology; D014568:Urokinase-Type Plasminogen Activator / Q000378:metabolism*
D000906:Antibodies; D000933:Antifibrinolytic Agents; D014361:Trypsin Inhibitors; D010450:Endopeptidases; D014568:Urokinase-Type Plasminogen Activator